Back to top
more

Assertio (ASRT)

(Real Time Quote from BATS)

$0.72 USD

0.72
121,182

+0.01 (1.05%)

Updated Aug 4, 2025 02:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Do Options Traders Know Something About Assertio (ASRT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Zacks Equity Research

ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study

by Zacks Equity Research

ImmunoGen (IMGN) reports successful completion of a pivotal study evaluating its lead pipeline candidate as monotherapy in certain ovarian cancer patients previously treated with Avastin.

Zacks Equity Research

Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval

by Zacks Equity Research

The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.

Zacks Equity Research

Assertio (ASRT) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 300.00% and 15.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Assertio (ASRT) Q3 Earnings Expected to Decline

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for September 9th

by Zacks Equity Research

ASRT, CVGW, NTRB, ITRG, and KNBWY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2021

Zacks Equity Research

New Strong Sell Stocks for September 7th

by Zacks Equity Research

ASRT, GLDD, MOGO, XPO, and FSUGY have been added to the Zacks Rank #5 (Strong Sell) List on September 7, 2021

Zacks Equity Research

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -300.00% and 24.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assertio (ASRT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aditi Saraogi headshot

Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options

by Aditi Saraogi

Investors need to pay close attention to for Assertio Holdings (ASRT) stock based on the movements in the options market lately.

Zacks Equity Research

Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.

Zacks Equity Research

Assertio (ASRT) Reports Next Week: What to Expect

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Do Options Traders Know Something About Assertio (ASRT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Assertio Holdings (ASRT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.

Zacks Equity Research

Assertio (ASRT) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 100.00% and 6.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Assertio (ASRT) Q3 Earnings Expected to Decline

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Assertio (ASRT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Assertio (ASRT) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

All You Need to Know About Assertio (ASRT) Rating Upgrade to Buy

by Zacks Equity Research

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.

Zacks Equity Research

Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -200.00% and 17.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.